Literature DB >> 12829823

Application of chimeric feline foamy virus-based retroviral vectors for the induction of antiviral immunity in cats.

Astrid Schwantes1, Uwe Truyen, Joachim Weikel, Christian Weiss, Martin Löchelt.   

Abstract

In order to define the potential and applicability of replication-competent foamy virus-based vaccine vectors, recombinant feline foamy virus (FFV) vectors encoding defined segments of the feline calicivirus (FCV) capsid protein E domain were constructed. In cell cultures, these FFV-FCV vectors efficiently transduced and expressed a hybrid fusion protein consisting of the essential FFV Bet protein and the attached FCV E domains. The stability of the vectors in vitro was inversely correlated to the size of the heterologous insert. The deletion of a part of the FFV U3 sequence in these FFV-FCV vectors did not interfere with replication and titer in cell cultures but increased the genetic stability of the hybrid vectors. Selected chimeric vectors were injected into immunocompetent cats and persisted in the transduced host concomitant with a strong and specific humoral immune response against vector components. In a substantial number of cats, antibodies directed against the FCV E domain were induced by the FFV-FCV vectors, but no FCV-neutralizing activities were detectable in vitro. When the vaccinated cats were challenged with a high-titer FCV dose, sterile immunity was not induced by any of the hybrid FFV-FCV vectors. However, the FFV-FCV vector with a truncated U3 region of the long terminal repeat promoter significantly reduced the duration of FCV shedding after challenge and suppressed the appearance of FCV-specific ulcers. Possible mechanisms contributing to the partial protection will be discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829823      PMCID: PMC161927          DOI: 10.1128/jvi.77.14.7830-7842.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Tissue distribution of virus replication in cats experimentally infected with distinct feline calicivirus isolates.

Authors:  U Truyen; K Geissler; J Hirschberger
Journal:  Berl Munch Tierarztl Wochenschr       Date:  1999-09       Impact factor: 0.328

2.  Location of monoclonal antibody binding sites in the capsid protein of feline calicivirus.

Authors:  I D Milton; J Turner; A Teelan; R Gaskell; P C Turner; M J Carter
Journal:  J Gen Virol       Date:  1992-09       Impact factor: 3.891

Review 3.  Regulation of foamy virus gene expression.

Authors:  A Rethwilm
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

4.  Construction of infectious feline foamy virus genomes: cat antisera do not cross-neutralize feline foamy virus chimera with serotype-specific Env sequences.

Authors:  M Zemba; A Alke; J Bodem; I G Winkler; R L Flower; K Pfrepper; H Delius; R M Flügel; M Löchelt
Journal:  Virology       Date:  2000-01-05       Impact factor: 3.616

5.  Human foamy virus genome possesses an internal, Bel-1-dependent and functional promoter.

Authors:  M Löchelt; W Muranyi; R M Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

6.  Analysis of feline calicivirus capsid protein genes: identification of variable antigenic determinant regions of the protein.

Authors:  B S Seal; J F Ridpath; W L Mengeling
Journal:  J Gen Virol       Date:  1993-11       Impact factor: 3.891

7.  Foamy virus vectors.

Authors:  D W Russell; A D Miller
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein.

Authors:  M Löchelt; R M Flügel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Transient immunosuppressive effect induced in rabbits and mice by the human spumaretrovirus prototype HFV (human foamy virus).

Authors:  M Santillana-Hayat; F Rozain; P Bittoun; C Chopin-Robert; J Lasneret; J Périès; M Canivet
Journal:  Res Virol       Date:  1993 Sep-Oct

10.  Detection and prevalence of serotypes of feline syncytial spumaviruses.

Authors:  R L Flower; G E Wilcox; R D Cook; T M Ellis
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

View more
  14 in total

1.  Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery.

Authors:  Michael Mühle; Kerstin Hoffmann; Martin Löchelt; Joachim Denner
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 2.  Role of the single deaminase domain APOBEC3A in virus restriction, retrotransposition, DNA damage and cancer.

Authors:  Yaqiong Wang; Kimberly Schmitt; Kejun Guo; Mario L Santiago; Edward B Stephens
Journal:  J Gen Virol       Date:  2015-10-20       Impact factor: 3.891

3.  Identification of novel, highly expressed retroviral microRNAs in cells infected by bovine foamy virus.

Authors:  Adam W Whisnant; Timo Kehl; Qiuying Bao; Magdalena Materniak; Jacek Kuzmak; Martin Löchelt; Bryan R Cullen
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 4.  Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Authors:  Joachim Denner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

5.  Lentivirus restriction by diverse primate APOBEC3A proteins.

Authors:  Kimberly Schmitt; Kejun Guo; Miki Katuwal; Darayu Wilson; Courtney Prochnow; Ronda Bransteitter; Xiaojiang S Chen; Mario L Santiago; Edward B Stephens
Journal:  Virology       Date:  2013-05-04       Impact factor: 3.616

Review 6.  Feline foamy virus-based vectors: advantages of an authentic animal model.

Authors:  Weibin Liu; Janet Lei; Yang Liu; Dragana Slavkovic Lukic; Ann-Mareen Räthe; Qiuying Bao; Timo Kehl; Anne Bleiholder; Torsten Hechler; Martin Löchelt
Journal:  Viruses       Date:  2013-07-12       Impact factor: 5.048

7.  Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy.

Authors:  Janet Lei; Wolfram Osen; Adriane Gardyan; Agnes Hotz-Wagenblatt; Guochao Wei; Lutz Gissmann; Stefan Eichmüller; Martin Löchelt
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

8.  Feline Foamy Virus Infection: Characterization of Experimental Infection and Prevalence of Natural Infection in Domestic Cats with and without Chronic Kidney Disease.

Authors:  Carmen Ledesma-Feliciano; Ryan M Troyer; Xin Zheng; Craig Miller; Rachel Cianciolo; Matteo Bordicchia; Nicholas Dannemiller; Roderick Gagne; Julia Beatty; Jessica Quimby; Martin Löchelt; Sue VandeWoude
Journal:  Viruses       Date:  2019-07-19       Impact factor: 5.048

9.  Replacement of feline foamy virus bet by feline immunodeficiency virus vif yields replicative virus with novel vaccine candidate potential.

Authors:  Carmen Ledesma-Feliciano; Sarah Hagen; Ryan Troyer; Xin Zheng; Esther Musselman; Dragana Slavkovic Lukic; Ann-Mareen Franke; Daniel Maeda; Jörg Zielonka; Carsten Münk; Guochao Wei; Sue VandeWoude; Martin Löchelt
Journal:  Retrovirology       Date:  2018-05-16       Impact factor: 4.602

Review 10.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.